A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus bisphosphonate in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral-quantitative computed tomography (p-QCT)

Trial Profile

A double-blind, multicentric, multinational randomised study to assess the effects of two years administration of 2 g per day of strontium ranelate versus bisphosphonate in women with postmenopausal osteoporosis on bone geometry and bone strength measured by peripheral-quantitative computed tomography (p-QCT)

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2013

At a glance

  • Drugs Strontium ranelate (Primary) ; Alendronic acid; Bisphosphonates
  • Indications Postmenopausal osteoporosis
  • Focus Registrational; Therapeutic Use
  • Acronyms STRATEC
  • Sponsors Servier
  • Most Recent Events

    • 08 Jun 2012 Actual end date changed from 30 Mar 2011 to 7 Apr 2011 as reported by European Clinical Trials Database.
    • 08 Jun 2012 Planned number of patients changed from 80 to 148, and trial locations added as reported by European Clinical Trials Database.
    • 30 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top